Autolus Therapeutics

Focus: Autolus Therapeutics is a UK-based biotechnology company specializing in CAR-T cell therapy for oncology and cell/gene therapy applications. The company operates as a focused biotech player in the advanced cell therapy space.

Cell Therapy Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Autolus Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Autolus Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

13 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Out-of-specification obecabtagene autoleucel

Lymphoblastic Leukemia, Acute, Adult

N/A

Clinical Trials (1)

NCT06799221Expanded Access Program for OOS Obe-cel

N/A

Help build intelligence for Autolus Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused expertise in CAR-T cell therapy, a high-growth, innovative segment with significant clinical and commercial potential
UK-based operations offering European biotech career opportunity with proximity to London's growing life sciences cluster
Specialization in cutting-edge cell and gene therapy modalities that are reshaping oncology treatment paradigms

Watch Out For

Currently no open job positions reported, indicating potential hiring freeze or reduced near-term expansion plans
Minimal public data on financial health, pipeline depth, or clinical trial activity limits visibility into company stability and trajectory

Generated by Claude from Autolus Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

AUTO1

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

Phase 1

Clinical Trials (1)

NCT06173518A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Phase 1

Obecabtagene autoleucel

Progressive Multiple Sclerosis

Phase 1

Clinical Trials (1)

NCT07139743Obe-cel in Refractory Progressive Forms of Multiple Sclerosis

Phase 1

Obecabtagene autoleucel

Systemic Lupus Erythematosus

Phase 1

Clinical Trials (1)

NCT06333483Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus

Phase 1

AUTO4

T Cell Non-Hodgkin Lymphoma

Phase 1/2

Clinical Trials (1)

NCT03590574Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma

Phase 1/2

AUTO3

B Acute Lymphoblastic Leukemia

Phase 1/2

Clinical Trials (1)

NCT03289455CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)

Phase 1/2

AUTO2

Multiple Myeloma

Phase 1/2

Clinical Trials (1)

NCT03287804APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma

Phase 1/2

AUTO3

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2

Clinical Trials (1)

NCT03287817Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma

Phase 1/2

AUTO1

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

Phase 1/2

Clinical Trials (1)

NCT04404660A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Phase 1/2

Obecabtagene Autoleucel

Acute Lymphoblastic Leukemia

Phase 2

Clinical Trials (1)

NCT07400029A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia

Phase 2

AUTO CAR T cell therapy

Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy

Phase 2

Clinical Trials (1)

NCT03628612Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells

Phase 2

Obecabtagene autoleucel

Lupus Nephritis

Phase 2

Clinical Trials (1)

NCT07053800Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis

Phase 2

Obecabtagene autoleucel

Acute Lymphocytic Leukemia (ALL)

Phase 2

Clinical Trials (1)

NCT07053059Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)

Phase 2